{
}
UBS analyst Eliana Merle has reiterated a Buy rating for Vertex Pharmaceuticals, setting a target price of $583.00, driven by strong momentum and expected growth in prescriptions for its drug Journavx, used for acute post-operative pain. The analysis indicates a potential increase in prescriptions, with positive feedback from healthcare professionals suggesting broader acceptance of the drug. Additionally, Vertex received European Commission approval for expanded use of its cystic fibrosis drug KAFTRIO®, further enhancing its market position.
A grant is set to advance CRISPR-based gene therapy targeting neurological disorders, with the global market projected to grow from USD 4.14 billion in 2023 to USD 18.84 billion by 2034, driven by rising demand for gene therapy and advancements in technology. The biomedical research segment leads in revenue, while North America is expected to dominate market share, with Asia Pacific showing the fastest growth. Notable collaborations, such as Vertex Pharmaceuticals and CRISPR Therapeutics, highlight the transformative potential of CRISPR in treating genetic conditions.
The convergence of science and technology is transforming healthcare, with Syfe's Healthcare Innovation portfolio offering diversified investment across genomics, biotechnology, pharmaceuticals, healthcare services, and medical devices. This portfolio includes six carefully selected ETFs, providing exposure to leading companies and innovations in the sector, while managing risks associated with long-term healthcare investments. With no minimum investment and low fees, it aims to capitalize on the future of healthcare advancements.
Vertex Pharmaceuticals Incorporated focuses on the discovery, development, and commercialization of micromolecular drugs aimed at treating cancer, viral, inflammatory, and autoimmune diseases. The company's net sales are distributed geographically, with 61.2% from the United States, 31.5% from Europe, and 7.3% from other regions. UBS has maintained a Buy recommendation for the company.
Vertex Pharmaceuticals reported Q3 earnings of $4.38 per share, exceeding estimates and showing a year-over-year increase from $4.08. Revenues reached $2.77 billion, surpassing expectations and up from $2.48 billion a year ago. Despite a 15.8% rise in shares this year, the stock holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market.
Jade Biosciences will merge with Aerovate Therapeutics in a reverse merger, allowing Jade to enter public markets under the ticker “JBIO.” The deal, expected to close in the first half of 2025, includes a $300 million private financing round and will see Jade's shareholders retain over 98% ownership of the combined entity. Jade's lead drug, targeting IgA nephropathy, is set to enter clinical trials in late 2024.
Vertex Pharmaceuticals (VRTX) is set to report its earnings on November 4, 2024, with expectations of a 1.2% year-over-year increase in earnings to $4.13 per share and a 7.8% rise in revenues to $2.68 billion. Recent estimate revisions indicate a positive outlook, with a 1.18% increase in the consensus EPS estimate over the last month. The company"s performance may significantly influence its stock price, depending on whether actual results meet or exceed these expectations.
Editas Medicine is seeking a partner or considering out-licensing its lead gene editing therapy, reni-cel, aimed at treating sickle cell disease and beta thalassemia. This shift comes as the company pivots from previous strategies and aims to reduce spending while advancing its research. Despite promising preclinical data, Editas faces challenges in bringing reni-cel to market, prompting a focus on in vivo gene editing for future treatments.
Otsuka Pharmaceutical's experimental drug, sibeprenlimab, has shown promising results in a Phase 3 trial for IgA nephropathy, a rare kidney disease, demonstrating a significant reduction in protein levels in urine, a key indicator of kidney health. The company plans to discuss accelerated approval with the FDA while the trial continues, expected to conclude in early 2026. This development validates Otsuka's acquisition of Visterra, which focuses on immune diseases, and positions sibeprenlimab as a potential first-in-class treatment for IgAN.
UBS has resumed coverage of Vertex Pharmaceuticals (NASDAQ:VRTX) with a buy rating, highlighting the company's significant growth potential. The investment bank projects a top-line compound annual growth rate (CAGR) of approximately 11% from 2023 to 2028, outpacing the estimated 5% growth of its large-cap peers.
Vertex Pharmaceuticals Incorporated
Companies
| Symbol | VRTX |
| Name | Vertex Pharmaceuticals Incorporated |
| Currency | USD |
| Sector | Health Care |
| IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences |
| Industry | Biotechnology |
| Market | NASDAQ Global Select |
| Country | United States |
| State | MA |
| City | Boston |
| Zipcode | 2210 |
| Website | http://www.vrtx.com |
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
ubs maintains buy rating for vertex with target price of 583 dollars
17:44 22.04.2025
advancements in crisper technology drive growth in gene editing market
United States Dollar
Vertex Pharmaceuticals Incorporated
Editas Medicine, Inc.
CRISPR Therapeutics AG
GBR
USA
Show more
17:45 13.01.2025
healthcare innovation portfolio targets advancements in pharmaceuticals and medical technologies
Masimo Corporation
Vertex Pharmaceuticals Incorporated
Abbott Laboratories
GE HealthCare Technologies Inc.
AtriCure, Inc.
Regeneron Pharmaceuticals, Inc.
Intuitive Surgical, Inc.
CRISPR Therapeutics AG
Veeva Systems Inc.
Johnson & Johnson
Cigna
Integra LifeSciences Holdings Corporation
CVS Health Corporation
Stryker Corporation
UnitedHealth Group Incorporated
Amgen Inc.
Penumbra, Inc.
Alphatec Holdings, Inc.
UCB SA
Boston Scientific Corporation
Eli Lilly and Company
USA
BEL
Beigene
Revolution Medicines
Gilead Sciences
Exelixis
Incyte
Show more
02:52 13.11.2024
vertex pharmaceuticals maintains strong market position with buy recommendation
18:02 05.11.2024
vertex pharmaceuticals reports strong q3 earnings and revenue growth
09:00 04.11.2024
jade biosciences to merge with aerovate in reverse merger deal
United States Dollar
Vertex Pharmaceuticals Incorporated
Travere Therapeutics, Inc.
Calliditas Therapeutics AB
Novartis AG
Biogen Inc.
USA
Tom Frohlich
Andrew King
Show more
17:18 31.10.2024
vertex pharmaceuticals earnings report expected to show growth and revenue increase
08:00 28.10.2024
editas seeks partner for gene editing therapy amid strategic shift
United States Dollar
Moelis & Company
Vertex Pharmaceuticals Incorporated
Genevant Sciences
CRISPR Therapeutics AG
Editas Medicine, Inc.
USA
Gilmore O’Neill
Dae Gon Ha
Show more
17:15 22.10.2024
otsuka's kidney disease drug shows promise in phase 3 trial results
Travere Therapeutics, Inc.
Biogen Inc.
Q32 Bio Inc.
Otsuka Pharmaceutical Co. Ltd.
Calliditas Therapeutics AB (publ)
Vera Therapeutics, Inc.
Vertex Pharmaceuticals Incorporated
Novartis AG
JPN
USA
Brian Pereira
John Kraus
Show more
16:51 22.10.2024
ubs resumes coverage of vertex pharmaceuticals with buy rating on growth potential
20:09 17.10.2024
Trending
Subcategory
Countries:
Companies:
Currencies:
People: